Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
THORAZINE (chlorpromazine) is an oral tablet small-molecule antipsychotic approved in 1957, representing one of the first-generation neuroleptics. It works as a dopamine antagonist across multiple indications in psychiatry and behavioral health. The drug treats schizophrenia, bipolar disorder, and severe behavioral disturbances, though its exact MOA details are not fully specified in available data.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating support and transitioning to lifecycle management or harvest mode.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
THORAZINE offers limited career development opportunities due to its mature, declining lifecycle stage and approaching loss of exclusivity; roles available are primarily defensive and focused on compliance, cost optimization, and niche patient populations. Career advancement on this product is constrained—most growth-oriented pharma professionals would seek positions on newer pipeline assets or growth-stage brands.
Worked on THORAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.